Cara Therapeutics, Inc. (NASDAQ:CARA) Given Consensus Rating of “Hold” by Brokerages

Shares of Cara Therapeutics, Inc. (NASDAQ:CARA) have earned a consensus recommendation of “Hold” from the five ratings firms that are currently covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold rating. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $27.84.

Separately, StockNews.com initiated coverage on shares of Cara Therapeutics in a research report on Tuesday. They set a “sell” rating on the stock.

Cara Therapeutics Stock Performance

Cara Therapeutics stock opened at $5.22 on Monday. The business’s fifty day moving average is $3.95 and its two-hundred day moving average is $3.79. The firm has a market cap of $23.85 million, a P/E ratio of -2.98 and a beta of 0.51. Cara Therapeutics has a 52 week low of $2.71 and a 52 week high of $13.80.

Institutional Trading of Cara Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC grew its position in shares of Cara Therapeutics by 18.5% during the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 32,789 shares during the period. XTX Topco Ltd acquired a new stake in Cara Therapeutics during the 3rd quarter worth $29,000. Finally, Disciplined Growth Investors Inc. MN raised its position in shares of Cara Therapeutics by 6.6% during the 2nd quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock valued at $499,000 after acquiring an additional 120,660 shares during the last quarter. 44.66% of the stock is owned by institutional investors.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.